Baillie Gifford & Co. Decreases Stock Position in Lyell Immunopharma, Inc. (NASDAQ:LYEL)

Baillie Gifford & Co. lowered its position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) by 72.7% during the third quarter, Holdings Channel.com reports. The institutional investor owned 141,949 shares of the company’s stock after selling 378,049 shares during the period. Baillie Gifford & Co.’s holdings in Lyell Immunopharma were worth $196,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in LYEL. Susquehanna Fundamental Investments LLC acquired a new stake in Lyell Immunopharma during the first quarter worth about $191,000. Acadian Asset Management LLC acquired a new stake in Lyell Immunopharma in the 1st quarter worth about $173,000. TD Asset Management Inc grew its holdings in shares of Lyell Immunopharma by 4.2% during the second quarter. TD Asset Management Inc now owns 1,004,642 shares of the company’s stock worth $1,457,000 after buying an additional 40,800 shares in the last quarter. The Manufacturers Life Insurance Company lifted its stake in shares of Lyell Immunopharma by 14.4% in the second quarter. The Manufacturers Life Insurance Company now owns 553,163 shares of the company’s stock worth $802,000 after buying an additional 69,712 shares in the last quarter. Finally, Exchange Traded Concepts LLC grew its stake in Lyell Immunopharma by 37.3% during the 3rd quarter. Exchange Traded Concepts LLC now owns 135,050 shares of the company’s stock valued at $186,000 after acquiring an additional 36,715 shares in the last quarter. Institutional investors and hedge funds own 66.05% of the company’s stock.

Lyell Immunopharma Price Performance

Shares of NASDAQ:LYEL opened at $1.10 on Thursday. The firm has a market capitalization of $307.14 million, a PE ratio of -1.39 and a beta of -0.47. Lyell Immunopharma, Inc. has a 1 year low of $0.85 and a 1 year high of $3.26. The firm’s 50-day moving average is $1.21 and its two-hundred day moving average is $1.69.

Lyell Immunopharma (NASDAQ:LYEL) last announced its quarterly earnings data on Thursday, November 7th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.03. Lyell Immunopharma had a negative return on equity of 34.64% and a negative net margin of 323,792.09%. The business had revenue of $0.03 million for the quarter. Analysts expect that Lyell Immunopharma, Inc. will post -0.85 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. Bank of America cut Lyell Immunopharma from a “buy” rating to an “underperform” rating and lowered their target price for the stock from $6.00 to $1.00 in a report on Wednesday, October 30th. HC Wainwright restated a “neutral” rating and issued a $1.00 price objective on shares of Lyell Immunopharma in a report on Tuesday.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.